Zealand Pharma A/s

Lise Giehm

Dieter Wolfgang Hamprecht

Jesper Mosolff Mathiesen

Henrik Kofoed Munch

Bjarne Due Larsen

Alistair Vincent Gordon Edwards

Alexander Heim-Riether

Jesper Skodborg Villadsen

Ditte Riber

Giacomo Fossati

Jonathan Griffin

Rasmus Just

Maria Alexandrovna Deryabina

Oliver Demmer

Jesper Sloth Villadsen

Jolanta Skarbaliene

Claes Melander

Henrik Rajesh Kumar Parshad

The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.

Amylin analogues

The present invention relates to glucagon analogues and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable glucagon analogues suitable for use in a liquid formulation.

Glucagon analogues

A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.

Acylated GLP-1/GLP-2 dual agonists

The invention relates to compounds having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors. The compounds find use, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.

GLP-1/GLP-2 dual agonists

The present invention relates to amylin analogs and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogs have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.

The present invention relates to glucagon analogs and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable glucagon analogs suitable for use in a liquid formulation.

Growing community of inventors

Frederiksberg, Denmark

Lise Giehm